Publications

Eisenberger, M., E. S. Garrett-Mayer, Y Ou Yang, R. de Wit, I. Tannock, and A. J. Armstrong. “A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Rich, J. N., M. L. Affronti, J. M. Day, J. E. Herndon, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, and H. S. Friedman. “Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Desjardins, A., D. P. Barboriak, J. E. Herndon, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, H. S. Friedman, and J. J. Vredenburgh. “Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Riedel, R. F., A. Porrello, E. Chenette, A. Potti, J. R. Nevins, and P. G. Febbo. “A genomic approach to identify mechanisms associated with chemotherapy resistance.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Vlahovic, G., T. L. Foster, C. H. Andrews, J. E. Herndon, T. Sporn, M. J. Kelley, M. W. Dewhirst, and Z. Vujaskovic. “Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Quinn, J. A., J. J. Vredenburgh, J. N. Rich, D. A. Reardon, A. Desjardins, S. Gururangan, A. H. Friedman, J. H. Carter, S. Threatt, and H. S. Friedman. “Phase II trial of Gliadel plus O-6-benzylguanic (O-6-BG) for patients with recurrent glioblastoma multiforme.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Anguiano, A., S. Mori, J. Chang, V. Vlahovic, M. J. Kelley, G. Ginsburg, H. Dressman, J. R. Nevins, and A. Potti. “A genomic signature of chemotherapeutic multidrug resistance provides a rational approach to identify patients for targeted therapy in advanced solid tumors.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Sathornsumetee, S., J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, M. J. Egorin, A. J. Salvado, H. S. Friedman, and D. A. Reardon. “Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Kelley, M. J., J. A. Bogart, L. D. Hodgson, R. H. Ansari, J. N. Atkins, X. F. Wang, M. R. Green, and E. E. Vokes. “CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Bota, D. A., A. Desjardins, J. A. Quinn, J. N. Rich, J. J. Vredenburgh, S. Sathornsumetee, K. Goli, A. Salvado, H. S. Friedman, and D. A. Reardon. “Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Scholars@Duke

Pages